The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 30, 2018

Filed:

Apr. 29, 2016
Applicant:

University of Waterloo, Waterloo, CA;

Inventors:

Frank Xiaofei Gu, Kitchener, CA;

Shengyan Liu, Waterloo, CA;

Lyndon William James Jones, Waterloo, CA;

Assignee:

UNIVERSITY OF WATERLOO, Waterloo, CA;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/13 (2006.01); A61K 9/16 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61K 49/00 (2006.01); A61K 9/51 (2006.01); A61K 31/131 (2006.01); A61K 31/69 (2006.01); A61K 31/78 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01);
U.S. Cl.
CPC ...
A61K 38/13 (2013.01); A61K 9/006 (2013.01); A61K 9/0048 (2013.01); A61K 9/1647 (2013.01); A61K 9/5123 (2013.01); A61K 9/5153 (2013.01); A61K 9/5161 (2013.01); A61K 9/5192 (2013.01); A61K 31/131 (2013.01); A61K 31/69 (2013.01); A61K 31/78 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61K 47/54 (2017.08); A61K 47/549 (2017.08); A61K 47/6935 (2017.08); A61K 47/6937 (2017.08); A61K 47/6939 (2017.08); A61K 49/0002 (2013.01); Y10T 428/2982 (2015.01);
Abstract

Disclosed is a mucoadhesive nanoparticle delivery system for delivering an immunosuppressant, such as cyclosporine A, to a mucosal site for treatment of a disease or condition involving inflammation or excess immune activity. The system comprises nanoparticles formed from a plurality of linear amphiphilic block copolymers, each having a hydrophobic block comprising polylactide (PLA) and a hydrophilic block comprising dextran. The nanoparticles are surface-functionalized with a mucosal targeting moiety, such as a phenylboronic acid derivative, for targeted delivery and enhanced retention at the mucosal site. Pharmaceutical compositions, methods, and uses thereof comprising the mucoadhesive nanoparticle delivery system are disclosed. The compositions can be administered in an effective amount for treating the disease or condition while substantially preserving or restoring the function and/or integrity of the mucosal lining. The composition may be formulated as an aqueous suspension for administration to an anterior surface of the eye in the treatment of dry eye syndrome.


Find Patent Forward Citations

Loading…